rutina

Rutin (Rutoside / Quercetin-3-O-Rutinoside)

1. Identity: Names, Chemistry, and Physical Properties

Rutin (rutoside, quercetin-3-O-rutinoside, or sophorin) is the glycoside combining the flavonol quercetin and the disaccharide rutinose (α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranose). The name "rutin" comes from the plant Ruta graveolens, which also contains rutin. Chemically it is a glycoside comprising flavonolic aglycone quercetin along with the disaccharide rutinose. It is also known as vitamin P or rutoside.

Rutin (3,3′,4′,5,7-pentahydroxyflavone-3-rhamnoglucoside) is a flavonoid of the flavonol-type that is widespread in the plant kingdom. Rutin is a light yellow or light green crystalline powder. Its CAS registry number is 153-18-4, and its molecular weight is 610.5 g/mol. The full IUPAC name is 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one. The molecular formula is C₂₇H₃₀O₁₆. Its biological activities are attributed to the presence of four hydroxyl groups and a rutinose molecule in its structure.

Rutin is synthesized through the phenylpropanoid metabolic pathway, which involves the transformation of the amino acid phenylalanine to 4-coumaroyl-CoA. After quercetin is catalyzed by UDP-glucose flavonoid 3-O-glucosyltransferase (UFGT) to form isoquercitrin, the formation of rutin from isoquercitrin is catalyzed by flavonoid 3-O-glucoside L-rhamnosyltransferase. The biosynthesis of rutin is regulated by ultraviolet light, and its accumulation in plants serves as a protection mechanism.

In the mid-1930s, Hungarian scientist Albert Szent-Györgyi first separated the flavonoid mixture. After the German pharmacy first made it into a preparation in 1942, the concept of "vitamin P" was established worldwide. Further study proved that rutin was the most important flavonoid of vitamin P.

2. Natural Sources and Distribution

Rutin is a unique antioxidant flavonoid that is mainly found in fruit, vegetables, cereals, and many other plant-based human diets. It is a plant-derived natural flavonoid mainly found in buckwheat flour, apples, citrus fruits, tea, and red wine.

More than 70 plant species are good sources of rutin, including Ruta graveolens L. (Rutaceae), Sophora japonica L. (Fabaceae), Strelitzia reginae Banks ex Aiton (Strelitziaceae), Maranta leuconeura (Marantaceae), Orchidantha maxillarioides (Lowiaceae), Eucalyptus spp. (Myrtaceae), Canna indica L. (Cannaceae), and Canna edulis Ker Gawl. (Cannaceae). The content of rutin in the flower buds of Sophora japonica is as high as 20%, and Sophora japonica is often used as the primary raw material for industrial extraction of rutin. Up to 1.5% of rutin can also be extracted from tobacco leaves.

Various citrus fruit peels contain 32 to 49 mg per g of flavonoids expressed as rutin equivalents. Citrus leaves contain rutin at concentrations of 11 mg per g in orange trees and 7 mg per g in lime trees. Rutin is also found in buckwheat, the leaves and petioles of Rheum species, and asparagus. In the leaves and flowers of certain plant species, rutin concentration can be as high as 2–10% of plant weight. The content of rutin at various parts of the plant considerably depends on its geographical source and genetic type.

3. Common Forms and Preparations

In many clinical trials and prescription products, "rutosides" refer to hydroxyethylrutosides (also called oxerutins), a standardized mixture of hydroxyethylated rutin derivatives. Troxerutin is another semisynthetic rutoside, derived from rutin but modified to improve water solubility and oral absorption. Natural rutin supplements are often marketed as general vascular and antioxidant support, while medicinal rutosides are used more specifically as venoactive drugs for chronic venous insufficiency and related microcirculatory disorders.

Capsules or tablets typically contain 50–500 mg of rutin per serving and are frequently combined with vitamin C, hesperidin, citrus bioflavonoids, or other botanicals aimed at vein or antioxidant support. Oxerutins (hydroxyethylrutosides) are a group of semisynthetic chemicals derived from rutin that have been widely used in Europe since the mid-1960s as a treatment for conditions in which blood or lymph vessels leak fluid. Rutin is also available in topical gel formulations for local vascular applications. Industrial use of rutin is still limited due to its low solubility in aqueous media, its characteristic bitter and astringent taste, and its susceptibility to degradation during processing; to expand its applications and preserve its biological activity, novel encapsulation systems have been developed.

4. Traditional and Historical Use

4.1 Ruta graveolens and Mediterranean Traditions

The most noteworthy application of R. graveolens is traditional medicine in diverse cultures worldwide. In countries such as Iran, it is known as the "cure-all" because of its broad therapeutic range, including anti-parasitic, analgesic, and anti-inflammatory effects, and its use in gynecological disorders. In Mediterranean traditional medicine, Ruta has been used to treat pulmonary conditions such as tuberculosis, and to reduce swelling of the spleen, as well as externally to treat wounds. Rue was also used in ancient Greece and Egypt to strengthen eyesight.

In folk medicine, rue has been used as an antispasmodic, sedative, and stimulant for the onset of menses. Rue has also been used to treat ailments such as earache, eye strain, multiple sclerosis, Bell palsy, and heart conditions.

4.2 Traditional Chinese Medicine

In traditional Chinese medicine, R. graveolens is slightly bitter, pungent, flat, and cool, and belongs to the lung, kidney, liver, and heart meridians. Its official name in Chinese is Yun Xiang, and its folk names include Chou Cao, Xiao Xiang Cao, Jin Jie Qi, and Xiang Cao. Dried or fresh whole plants, including roots, stems, and leaves, are used in traditional Chinese medicine to remove heat and toxic materials, disperse stasis, and relieve pain.

4.3 Ayurvedic and Other Traditions

Traditionally derived from buckwheat seeds, citrus fruits, and medicinal plants, rutin has been a keystone of therapeutic uses in Ayurveda, Traditional Chinese Medicine (TCM), and European herbal traditions. Traditional Chinese Medicine and even Russian folk traditions employed buckwheat-based preparations for "blood tonic" effects, though they did not identify the active compound explicitly as rutin.

4.4 Vascular Applications in European Medicine

By the mid-20th century, rutin's vascular-support effects emerged prominently in European herbal traditions, especially for varicose veins and hemorrhoids. Rutin was found effective in the treatment of several conditions including varicosities, haemorrhoids, and internal haemorrhage. Rutin has also been used with the potential to prevent retinal haemorrhage and cerebral accidents in patients.

5. Key Constituents and Active Compounds

Rutin is itself a single defined phytochemical rather than a mixture, but it is important to understand its structural features and their relationship to biological activity. The presence of four hydroxyl groups and a rutinose molecule in the rutin structure are considered responsible for its biological activities. Flavonoids, including rutin, are polyphenolic compounds that contain a benzopyrone moiety.

When rutin is consumed orally, colonic bacteria cleave the rutinose sugar group, releasing the aglycone quercetin. In clinical trials studying the effects of quercetin derived from rutin, bioavailability must be taken into consideration and plasma quercetin concentrations monitored. The metabolism of rutin is substantially dependent on gut microbiota composition, which means inter-individual variability in response to rutin supplementation is expected.

6. Established Mechanisms of Action

6.1 Antioxidant Activity

Modern studies validate rutin's multifaceted bioactivities, including strong antioxidant, anti-inflammatory, antimicrobial, neuroprotective, cardioprotective, and anticancer activities. Rutin is a powerful antioxidant capable of scavenging free radicals and reducing oxidative stress. Rutin can suppress the prooxidant actions of some other flavonoids, and unlike certain other flavonoids such as apigenin, it demonstrates a lack of cytotoxicity against normal human cells.

6.2 Anti-inflammatory Mechanisms

Rutin has demonstrated protective effects on histopathological changes in lung tissue along with prevention of infiltration of polymorphonuclear granulocytes in bronchoalveolar lavage fluid. There was also a reduction in secretion of lipid peroxidation and proinflammatory cytokines. The activity of antioxidant enzymes such as catalase, glutathione peroxidase, superoxide dismutase, and heme oxygenase-1 caused by lipopolysaccharide was reversed by rutin.

Pretreatment with rutin caused inhibition of lipopolysaccharide-induced arterial blood gas exchange and neutrophil infiltration in the lungs, with suppression of macrophage inflammatory protein-2 and matrix metalloproteinase-9. Another study demonstrated that rutin effectively inhibited vascular cell adhesion molecule-1 and inducible nitric oxide synthase.

Rutin exerts anti-inflammatory effects in ultraviolet B-irradiated mouse skin by inhibiting the expression of cyclooxygenase-2 and inducible nitric oxide synthase. Rutin suppressed activity of proinflammatory cytokines by diminishing TNF-α and IL-1β production in microglia.

6.3 Vascular and Endothelial Effects

Rutin is particularly known for its beneficial effects on vascular health. By strengthening capillary walls, it reduces their permeability and fragility and helps prevent edema and improve blood circulation. Studies show that rutin improves endothelial function by increasing the production of nitric oxide, a natural vasodilator, in human endothelial cells. This helps regulate blood pressure and reduces vascular inflammation, making it relevant in the treatment of chronic venous disorders such as varicose veins and venous insufficiency.

6.4 Antithrombotic Mechanism via Protein Disulfide Isomerase (PDI)

Quercetin-3-rutinoside (rutin) inhibits thrombus formation in a mouse model by inhibiting extracellular protein disulfide isomerase (PDI), an enzyme required for platelet thrombus formation and fibrin generation. PDI is a thiol isomerase that catalyzes disulfide formation, reduction, and isomerization. The extracellular PDI plays an important role in the initiation of clot formation by regulating the oxidation states of labile disulfide bonds in critical hemostatic proteins, including platelet surface receptors αIIbβ3 and GPIbα, adhesive proteins TSP-1 and vitronectin, and coagulation factors. Inhibition of PDI by rutin blocked both platelet aggregation and fibrin generation in vivo at a dose of 0.5 mg kg⁻¹ in mouse models.

Results consistently showed that the PDI residues H354, L355, and E359 are important in the binding of rutin. These residues are next to the canonical major substrate binding site of the b′ domain and were not conserved across the members of thiol isomerases, explaining the specificity of rutin for PDI among vascular thiol isomerases. A close analog of rutin, isoquercetin, is currently in advanced phase clinical trials for antithrombotic indications, providing translational relevance to this mechanism.

6.5 Atherosclerosis-Related Mechanisms

Rutin could suppress the generation of inflammatory factors and reactive oxygen species (ROS) in ox-LDL-induced macrophages and enhance their polarization. Moreover, rutin decreased foam cell production, as shown by oil red O staining, and increased the number of autophagosomes and the LC3II/I ratio while lowering p62 expression. Furthermore, rutin could significantly inhibit the PI3K/ATK signaling pathway. In summary, rutin inhibits ox-LDL-mediated macrophage inflammation and foam cell formation by inducing autophagy and modulating PI3K/ATK signaling, showing potential in treating atherosclerosis.

6.6 Neuroprotective Mechanisms

Rutin's multifaceted neuroprotective mechanisms encompass antioxidant, anti-inflammatory, anti-apoptotic, antidepressant, anticonvulsant, and analgesic effects, as well as a role in enhancing neural signal transduction, improving learning and memory, and protecting the blood-brain barrier.

Rutin protects against the neurodegenerative effects of prion accumulation by increasing the production of neurotrophic factors and inhibiting apoptotic pathway activation in neuronal cells. Rutin caused attenuation of streptozotocin-induced inflammation by decreasing the activity of glial fibrillary acidic protein, interleukin-8, cyclooxygenase-2, inducible nitric oxide synthase, and nuclear factor-κB, and thereby prevented gross anatomical changes in the rat hippocampus. Such an effect could be useful in averting cognitive deficits and may prove beneficial in the treatment of "sporadic dementia of Alzheimer type."

6.7 Anticancer Signaling Pathways

Rutin interferes with cancer progression by inducing apoptosis and autophagy, promoting cell cycle arrest, regulating oxidative stress, activating tumor suppressor genes, and modulating various signaling cascades. Rutin alone or in combination with other therapeutic agents has been shown to regulate several signalling pathways involving the Ras/Raf and PI3K/Akt, MAPK, and TGF-β2/Smad2/3Akt/PTEN, which are related to the processes of carcinogenesis and induction of apoptosis.

7. Scientific Evidence by Health Area

7.1 Chronic Venous Insufficiency (CVI)

According to a Cochrane review, rutin, classified as a phlebotonic, has primarily been studied for its effects in the treatment of chronic venous insufficiency (CVI). It acts by slightly reducing edema of the lower limbs (an effect measured by ankle circumference and leg volume), while improving symptoms such as pain, heaviness, and itching.

One of the most studied areas for rutin-type compounds is chronic venous insufficiency and related vein problems. In this condition, leg veins struggle to return blood to the heart, leading to heaviness, swelling, night cramps, and visible varicose veins. Clinical trials of hydroxyethylrutosides (semisynthetic derivatives of rutin) show modest improvements in symptoms such as leg pain, heaviness, and edema when used alongside standard measures like compression. These data suggest that rutin-type flavonoids can help tone the venous wall and reduce capillary leakage, although they are not a replacement for compression stockings or surgery where needed.

Several randomized, double-blind, controlled clinical trials involving a significant number of patients have produced consistently positive conclusions for this indication. However, much of this evidence is based on semi-synthetic oxerutin/hydroxyethylrutinoside formulations rather than unmodified natural rutin, and comparability must be interpreted cautiously. Overall, the benefits of rutosides are most solidly supported for short-term symptom relief in CVI.

A notable single-centre, randomised, double-blind, placebo-controlled clinical trial (Eur J Clin Pharmacol, 1996) examined buckwheat herb tea — a natural rutin-rich preparation — in patients with CVI, demonstrating leg oedema protection. This study is cited in the literature as one of the few trials directly involving a natural rutin source rather than a synthetic derivative.

7.2 Hemorrhoids

Rutosides have been used to reduce pain and swelling in hemorrhoidal disease, with variable but sometimes positive results. For hemorrhoids and chronic venous insufficiency, clinical studies have typically used rutin derivatives (hydroxyethylrutosides or troxerutin) rather than plain rutin, often at higher doses than standard supplements. One clinical trial used a flavonoid blend containing rutin, diosmin, troxerutin, hesperidin, and quercetin to treat hemorrhoidal disease across severity grades, reporting significant improvement in bleeding and minimal side effects. Clinical studies of rutoside in some form for hemorrhoids date back to at least 1970.

7.3 Antithrombotic / Cardiovascular

Rutin, as quercetin-3-O-rutinoside, was identified to block thrombus formation in the mouse model and reduce thrombin generation in humans through targeting the extracellular protein disulfide isomerase (PDI). Further studies and clinical translation were restricted due to its low aqueous solubility and oral bioavailability.

Rutin, one of the most potent PDI inhibitors, was reported to suppress platelet aggregation and thrombosis in animal models, but further studies and clinical translation were restricted due to its low aqueous solubility and oral bioavailability. Researchers have fabricated rutin-loaded lipid-based nano-formulations to address these issues. At present, direct evidence in humans for antithrombotic effects of orally administered native rutin remains limited, with most evidence from preclinical (animal and in vitro) models or from human studies showing reduction of thrombin generation rather than clinical endpoints.

7.4 Neuroprotection

Neurological diseases, including stroke, Alzheimer's disease, Parkinson's disease, and diabetic neuropathy, pose a significant global health burden. The rising incidence of these diseases has intensified the need for effective neuroprotective therapies. Rutin, widely distributed in various plants including buckwheat, citrus fruits, and onions, has garnered significant attention as a promising neuroprotective agent.

Rutin is a promising agent for the treatment of Alzheimer's disease because of its antioxidant, anti-inflammatory, and β-amyloid oligomer-reducing activities. Nitric oxide modulation could possibly be involved in the neuroprotective effects of rutin against head trauma-induced cognitive deficits, neuroinflammation, and apoptotic signaling cascade. Important limitation: Rutin's journey to clinical application faces challenges including its relatively low bioavailability, chemical instability under certain conditions including light, heat, and pH, pharmacokinetic limitations, potential interactions with other medications, and an incompletely characterized safety profile with long-term use or at high doses. These limitations have dampened its therapeutic potential in humans despite its efficacy in preclinical models. Evidence for neuroprotective effects in humans currently remains preliminary.

7.5 Antioxidant Status in Humans

Eighteen volunteers completed a human supplementation trial. Rutin supplementation did not induce any adverse changes in blood chemistry or indices of liver function. Plasma flavonoids were significantly elevated in the rutin-supplemented group. Six weeks of rutin supplementation significantly elevated the levels of three plasma flavonoids including quercetin. However, this elevation in plasma flavonoids did not translate into a statistically significant reduction in all oxidative damage markers measured (urinary 8-OHdG, urinary malondialdehyde), indicating that higher plasma levels do not automatically confer commensurate antioxidant protection at the whole-organism level.

7.6 Inflammatory Bowel Disease / Colitis

Preclinical evidence suggests that rutin can significantly alleviate the abnormal indicators of intestinal inflammation. In experiments, the performance of rutin in various indicators is very close to existing positive control drugs such as sulfasalazine and budesonide, with similar therapeutic effects. The findings from these studies indicate that rutin has a significant positive impact on various indicators of intestinal disease caused by IBD. Key results include reduced weight loss, lower disease activity index (DAI), decreased inflammatory markers, reduced oxidative stress markers, and increased antioxidant defenses. Its mechanism of action involves anti-inflammatory and antioxidant effects, inhibition of inflammatory signaling pathways, barrier protection, inhibition of adaptive immune responses, restoration of intestinal permeability, and regulation of microbiota. Evidence in this area remains largely preclinical (animal models); direct human clinical trial data are sparse.

7.7 Anticancer Properties

Rutin is demonstrated to inhibit the proliferation of breast, colon, lung, and prostate cancers and other tumors in preclinical (in vitro and animal) models. The combination of rutin with other chemotherapy drugs may benefit the prevention of tumor cell growth by decreasing drug resistance and chemotherapy side effects. Moreover, rutin induces apoptosis synergistically with therapeutic agents. Recent studies also suggest that combining rutin with other therapeutic agents or employing nanoformulations may enhance its bioavailability and anticancer efficacy. Critical note: Anticancer evidence for rutin is predominantly derived from in vitro and animal studies. No human clinical trials have established rutin as an anticancer treatment.

7.8 Antimicrobial Activity

Pharmacological studies demonstrate that rutin has broad-spectrum antimicrobial activity against bacterial and fungal pathogens such as Staphylococcus aureus and Candida krusei, and synergistically improves standard antibiotic and antifungal treatments. Rutin has demonstrated antibacterial efficacy against P. aeruginosa, Staphylococcus aureus, and Escherichia coli, perhaps via mechanisms such as K⁺ leakage. This evidence is derived from in vitro and preclinical studies; human clinical data for antimicrobial indications are absent.

7.9 Diabetes and Metabolic Effects

Rutin exhibited significant antidiabetic activity, presumably by inhibiting inflammatory cytokines, and improved the antioxidant and plasma lipid profiles in a high fat diet + streptozotocin-induced type 2 diabetic animal model. Rutin may thus be useful as a diabetic modulator along with standard antidiabetic drugs. Human trials have not been done for metabolic/obesity effects, but in rodent models, supplementation with rutin has been found to decrease obesity by creating a better balance of brown adipose tissue vs. white adipose tissue composition. Evidence in this area in humans is therefore limited to preliminary or indirect observations.

8. Body Systems and Health Areas Associated with Rutin

• Vascular / Circulatory System: Capillary strength, venous tone, reduction of capillary permeability, chronic venous insufficiency, edema, hemorrhoids.
• Cardiovascular System: Atherosclerosis (lipid peroxidation and foam cell inhibition), antithrombotic activity via PDI inhibition, blood pressure (via nitric oxide production).
• Nervous System: Neuroprotection, anti-Alzheimer potential, anticonvulsant activity, blood-brain barrier protection.
• Metabolic System: Antidiabetic effects (animal models), lipid profile improvement, adipose tissue modulation.
• Gastrointestinal System: Gastroprotection, inflammatory bowel disease symptom attenuation (preclinical).
• Immune System: Broad anti-inflammatory signaling (NF-κB, TNF-α, IL-1β, COX-2 pathways), antimicrobial properties.
• Oncology: Preclinical anticancer activity across multiple cancer cell lines.

Rutin has a variety of pharmacological effects including antioxidant, anti-inflammatory, antihypertensive, maintenance of vascular elasticity, and neuroprotection.

9. Dosage Forms and Doses Reported in Studies

For varicose veins and venous insufficiency, oxerutins (hydroxyethylrutosides) are usually taken in dosages ranging from 600 to 1,200 mg daily. A typical schedule is 1,000 mg daily, taken in two separate 500 mg doses. For treating lymphedema and postsurgical edema, a typical dosage used in studies is considerably higher at 3,000 mg daily. One particular oxerutin, troxerutin, may be taken alone in similar dosages as a treatment for varicose veins. These therapies have been safely used for up to twelve weeks in clinical studies.

For hemorrhoids and chronic venous insufficiency, clinical studies have typically used rutin derivatives (hydroxyethylrutosides or troxerutin) rather than plain rutin, often at higher doses than standard supplements. The 500 mg end of the dosing range is more common in research for vein problems or hemorrhoids, though the optimal dose for these conditions has not been formally established.

Inhibition of PDI by rutin blocked both platelet aggregation and fibrin generation in vivo at a dose of 0.5 mg kg⁻¹ in mouse models. Comparable effective human doses for antithrombotic purposes have not been established in clinical trials.

Supplement capsules or tablets typically contain 50–500 mg rutin per serving and are frequently combined with vitamin C, hesperidin, citrus bioflavonoids, or other botanicals. Oxerutins are available most commonly in 250 mg tablets.

Although rutin has significant therapeutic promise, its translation into the clinical setting is circumscribed by its limited aqueous solubility and bioavailability. Progress in recent nanoencapsulation and drug delivery techniques has endeavored to obviate these barriers, optimizing pharmacokinetics.

10. Bioavailability Considerations

Reported issues with rutin include a short shelf life, physicochemical and organoleptic deterioration due to environmental stress or the mixture of compounds during processing, uncontrolled release, instability under digestive conditions in the gastrointestinal tract, and low bioavailability.

The primary limitation of rutin is its restricted solubility in aquatic environments, resulting in reduced bioavailability. Rutin is a glycoside and must be hydrolyzed to quercetin by intestinal microbiota before meaningful absorption of the aglycone can occur; this renders bioavailability subject to individual gut microbiome composition. Plasma flavonoids were significantly elevated in the rutin-supplemented group in one human study, confirming measurable absorption, though the degree varies considerably among individuals.

A novel micellar chrysin–quercetin–rutin formulation substantially improved bioavailability and was well tolerated during 30 days of daily use, supporting its potential as an advanced delivery strategy for flavonoids with poor oral absorption.

11. Safety Considerations and Drug Interactions

11.1 General Safety Profile

In a human supplementation study, rutin supplementation did not induce any adverse changes in blood chemistry or indices of liver function. A distinguishing benefit of rutin, compared to other flavonoids such as apigenin, is its lack of cytotoxicity against normal human cells. Rutin also possesses anticonvulsant activity and seems to be safe for patients with epilepsy as it does not alter the activity of any of the administered antiepileptic drugs nor demonstrate any adverse effects in the studies reviewed. Oxerutin preparations have been safely used for up to twelve weeks in clinical trials.

11.2 Anticoagulant and Antiplatelet Interactions

A moderate drug interaction exists between rutin and warfarin. Because rutin inhibits PDI, thereby reducing platelet aggregation and thrombin generation, concurrent use with anticoagulant drugs such as warfarin or antiplatelet agents introduces a plausible additive bleeding risk. When given simultaneously, rutin increases the amount of paclitaxel absorbed by the body, and rutin treatment may further increase the body's resistance to certain medications.

One of the primary concerns is rutin's interaction with anticoagulant and antiplatelet drugs such as warfarin, aspirin, and clopidogrel. Additionally, rutin may interact with certain anti-inflammatory drugs (both steroidal and non-steroidal), potentially enhancing their effects and increasing the risk of gastrointestinal side effects like ulcers and bleeding.

11.3 Cytochrome P450 Interactions

Rutin may affect the metabolism of certain drugs processed by the liver's cytochrome P450 enzyme system. This can alter the blood levels and effectiveness of medications such as statins, certain antidepressants, and some antiepileptic drugs.

11.4 Pregnancy and Pediatric Populations

Data on safety of rutin supplementation during pregnancy or breastfeeding are insufficient to draw conclusions. Similarly, pediatric safety data are lacking. The rutin-containing parent plant Ruta graveolens contains additional compounds (furoquinoline alkaloids, furanocoumarins) that carry established toxicological concerns, including potential abortifacient effects; however, these concerns are attributed to the whole plant rather than to isolated rutin. Use of isolated rutin in pregnancy remains unstudied.

11.5 Stability and Processing Concerns

Rutin is chemically unstable under certain conditions, including light, heat, and pH. This instability is relevant both for the stability of commercial preparations and for the behavior of dietary rutin during food processing and cooking, where degradation can significantly reduce effective content.

References

• Iqubal A, et al. "Rutin: A Flavonoid as an Effective Sensitizer for Anticancer Therapy." PMC / NCBI, 2021.
• IntechOpen. "The Biomarker Flavonoid 'Rutin' in Morus Species: Isolation, Identification, and Characterization." 2024.
• Ganeshpurkar A, Saluja AK. "The Pharmacological Potential of Rutin." PMC / Saudi Pharmaceutical Journal, 2017.
• Wikipedia. "Rutin." (For chemical identity cross-reference only.)
• Allelopathy Journal. "Traditional uses and pharmacological properties of rutin." 2025.
• Drug Design, Development and Therapy / Dove Medical Press. "Traditional uses, phytochemistry, pharmacology and toxicology of Ruta graveolens."
• Frontiers in Pharmacology / PMC. "Molecular mechanisms of neuroprotective effect of rutin." 2025.
• Al-Dhabi NA, et al. "An up-to-date review of rutin and its biological and pharmacological activities." EXCLI Journal / PMC, 2015.
• PMC. "Rutin Inhibits Ox-LDL-Mediated Macrophage Inflammation and Foam Cell Formation by Inducing Autophagy and Modulating PI3K/ATK Signaling." 2022.
• PMC. "Assessing the therapeutic potential of rutin in alleviating symptoms of inflammatory bowel disease: a meta-analysis." 2025.
• PMC. "Molecular basis of rutin inhibition of protein disulfide isomerase (PDI) by combined in silico and experimental methods." 2022.
• PMC. "Orally delivered rutin in lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibition." 2022.
• Erlund I, et al. "Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study." PubMed, 2000.
• Erlund I, et al. "Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers." PubMed, 2000.
• PMC. "Rutin: Family Farming Products' Extraction Sources, Industrial Applications and Current Trends in Biological Activity Protection." 2023.
• EBSCO Research Starters. "Oxerutins' therapeutic uses." (Vitalibrary/EBSCO.)
• PMC. "The potential role of rutin, a flavonoid, in the management of cancer through modulation of cell signaling pathways." 2025.
• PMC. "Real-World Evaluation of the Interaction Between Rifampicin and Warfarin." (Reference for herb-drug interaction context.) 2025.
• Ge B, et al. "Updates on the Clinical Evidenced Herb-Warfarin Interactions." PMC, 2014.
• PMC. "Comparative Pharmacokinetics and Safety of a Micellar Chrysin–Quercetin–Rutin Formulation: A Randomized Crossover Trial." 2025.
• PMC. "Rutin Promotes Wound Healing by Inhibiting Oxidative Stress and Inflammation in Metformin-Controlled Diabetes in Rats." 2024.